Business Description
4D Molecular Therapeutics Inc
NAICS : 325412
SIC : 2834
Description
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.86 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 11.76 | |||||
| Beneish M-Score | -3.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.9 | |||||
| 3-Year EBITDA Growth Rate | -2.9 | |||||
| 3-Year EPS without NRI Growth Rate | 5.5 | |||||
| 3-Year FCF Growth Rate | -4.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | -36.44 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 5.56 | |||||
| 9-Day RSI | 13.7 | |||||
| 14-Day RSI | 21.13 | |||||
| 6-1 Month Momentum % | 0.42 | |||||
| 12-1 Month Momentum % | 108.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.11 | |||||
| Quick Ratio | 23.11 | |||||
| Cash Ratio | 22.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30 | |||||
| Shareholder Yield % | -68.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -5142.6 | |||||
| Net Margin % | -4876.01 | |||||
| ROE % | -42.87 | |||||
| ROA % | -38.63 | |||||
| ROIC % | -247.27 | |||||
| ROC (Joel Greenblatt) % | -338.03 | |||||
| ROCE % | -42.78 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 211.18 | |||||
| PB Ratio | 1.86 | |||||
| Price-to-Tangible-Book | 1.8 | |||||
| EV-to-EBIT | -2.66 | |||||
| EV-to-EBITDA | -2.78 | |||||
| EV-to-Revenue | 136.84 | |||||
| EV-to-Forward-Revenue | 130.21 | |||||
| EV-to-FCF | -3.19 | |||||
| Price-to-Net-Current-Asset-Value | 2.01 | |||||
| Price-to-Net-Cash | 2.06 | |||||
| Earnings Yield (Greenblatt) % | -37.59 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FDMT
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
4D Molecular Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.284 | ||
| EPS (TTM) ($) | -3.28 | ||
| Beta | 0 | ||
| Volatility % | 182.86 | ||
| 14-Day RSI | 21.13 | ||
| 14-Day ATR ($) | 0.630439 | ||
| 20-Day SMA ($) | 15.7605 | ||
| 12-1 Month Momentum % | 108.63 | ||
| 52-Week Range ($) | 6.58 - 26.49 | ||
| Shares Outstanding (Mil) | 42.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
4D Molecular Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
4D Molecular Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
4D Molecular Therapeutics Inc Frequently Asked Questions
What is 4D Molecular Therapeutics Inc(FDMT)'s stock price today?
The current price of FDMT is $13.91. The 52 week high of FDMT is $26.49 and 52 week low is $6.58.
When is next earnings date of 4D Molecular Therapeutics Inc(FDMT)?
The next earnings date of 4D Molecular Therapeutics Inc(FDMT) is 2023-11-08 Est..
Does 4D Molecular Therapeutics Inc(FDMT) pay dividends? If so, how much?
4D Molecular Therapeutics Inc(FDMT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers